Media Alert – COVID-19 New Findings: FLCCC Alliance News Conference

Prophylaxis & Treatment Protocols for Covid-19
Front Line COVID-19 Critical Care Alliance (FLCCC Alliance)

A team of highly published, ICU critical care physician/scholars have conducted a comprehensive analysis of the rapidly accumulating scientific study data from centers around the world supporting the efficacy of a repurposed oral medication. The team will announce the results of its research that demonstrates the consistent, reproducible, and high effectiveness of this safe, inexpensive, and globally available oral agent in both the prevention and treatment of COVID-19.  

The physicians will also call for immediate action from national health authorities to conduct a swift review of these data; with the goal of then being able to issue an urgent public health alert with recommendations for widespread distribution of this therapeutic that can significantly impact the current  surge in COVID-19 infections.  

When: Friday morning, December 4, at 10:30 am CST  

Where: United Memorial Medical Center in Houston, Texas  

510 West Tidwell Road, 77091  

Webinar registration: 

Who: Joe Varon, M.D., FCCP, FCCM 

− Chief of Staff and Chief of Critical Care Services at United Memorial Medical Center and United General Hospital  

− Former Chief of Staff at University General Hospital 

− Professor of Acute and Con+nuing Care at the University of Texas Health Science Center, CAP, Department of  Medicine, Baylor College of Medicine  

− Professor of Medicine and Surgery, UAT, UABC, UNE, USON, UPAEP, Mexico  

Paul Marik, M.D., FCCM, FCCP  

− Board certified in Internal Medicine, Cri+cal Care Medicine, Neurocritical Care and Nutrition Science 

− Professor of Medicine (with tenure) and Chief of the Division of Pulmonary and Critical Care Medicine, at Eastern Virginia Medical School in Norfolk, Virginia  

− Author of more than 450 peer-reviewed journal articles, 80 book chapters, and four critical care books  

− Cited over 36,000 times in peer-reviewed publications 

− Delivered more than 350 lectures at international conferences and visiting professorships  

− Recipient of numerous teaching awards including ‘National Teacher of the Year’ by the American College of Physicians in 2017  

− The second most published critical care doctor in the world  

Pierre Kory, M.D., M.P.A.  

− Associate Professor of Medicine, Board Certified in Critical Care, Pulmonary Diseases, and Internal Medicine  

− Advocate Aurora Critical Care Service, Aurora St. Luke’s Medical Center, Milwaukee,WI  

− Former Chief of the Critical Care Service and Medical Director of the Trauma and Life Support Center at the University of Wisconsin  

− Senior editor of the best-selling textbook, ‘Point of Care Ultrasound’ now translated into 6 languages,  

published expert on the use of therapeutic hypothermia after cardiac arrest and the efficacy of intravenous  

ascorbic acid in the treatment of severe infections and septic shock 


Additional Info  

Drs. Varon, Marik, and Kory are founding members of the Frontline COVID-19 Critical Care Alliance (FLCCC) a 501(c)(3) nonprofit organization formed by a group of Critical Care physician/scholars — with the academic  support of allied physicians from around the world — formed in March 2020, to research and develop lifesaving protocols for the prevention and treatment of COVID-19 in all stages of illness. The FLCCC doctors  share decades of experience in hospital ICUs and have published more than 1,000 scientific studies in leading medical journals. (The FLCCC is not associated in any way with the group called ‘America’s FrontlineDoctors’.) 

If you want to know more about the FLCCC Alliance please regard our “About” section on, in  particular the “FLCCC Alliance Story.”  

In addition our home page contains Scientific Reviews and many links to scientific studies that provide the medical evidence in support of our prophylaxis & treatment protocols for Covid-19.  

FLCCC Alliance – Mission Statement and ObjecOves  

Formed by leading critical care specialists in March 2020, at the beginning of the Coronavirus pandemic,  the ‘Front Line COVID-19 Critical Care Alliance’ is now a 501(c)(3) non-profit organization dedicated to developing highly effective treatment protocols to prevent the transmission of COVID-19 and to improve  the outcomes for patients ill with the disease.  

We are dedicated to  

− Reviewing all emerging published medical literature on COVID-19 from in-vitro, animal, clinical, and epidemiologic studies.  

− Developing effetive treatment protocols for COVID-19 that evolve by incorporating newly identified, applicable therapeutic and pathophysiologic insights.  

− Educating physicians on safe and effective treatment approaches to all phases of COVID-19, from disease prevetion strategies to the use of our combination-based therapy protocols in both early stage (I-MASK+) and hospitalized patients (MATH+).  

− Improving outcomes for people impacted by COVID-19 disorders through preventive and treatment strategies designed to optimize health.  

− Teaching the public ways to prevent transmission of the virus and to advocate for the best possible care.  

− Coordinating and accelerating the formation of research studies that will support effective prevention and therapeutic treatments for all impacted by COVID-19  

We accomplish these goals by sponsoring high quality medical education for both the public and health care providers, via the publication of scientific manuscripts, media interviews, and medical lectures for medical providers and the public. 

For more information about the FLCCC Alliance, the I-Mask+ Prophylaxis & Early Outpatient Treatment Protocol for COVID-19 and the MATH+ Hospital Treatment Protocol for COVID-19, please visit

Filters close

Showing results

110 of 4573
Released: 15-Jan-2021 5:40 PM EST
Research Links Social Isolation to COVID-19 Protocol Resistance
Humboldt State University

As health officials continue to implore the public to wear masks and practice social distancing, recent research by Humboldt State University Psychology Professor Amber Gaffney provides key insights into connections between social isolation, conspiratorial thinking, and resistance to COVID-19 protocols.

Newswise: Rapid blood test identifies COVID-19 patients at high risk of severe disease
Released: 15-Jan-2021 5:35 PM EST
Rapid blood test identifies COVID-19 patients at high risk of severe disease
Washington University in St. Louis

Scientists at Washington University School of Medicine in St. Louis have shown that a relatively simple and rapid blood test can predict which patients with COVID-19 are at highest risk of severe complications or death. The blood test measures levels of mitochondrial DNA, which normally resides inside the energy factories of cells. Mitochondrial DNA spilling out of cells and into the bloodstream is a sign that a particular type of violent cell death is taking place in the body.

Released: 15-Jan-2021 2:55 PM EST
COVID-19 deaths really are different. But best practices for ICU care should still apply, studies suggest.
Michigan Medicine - University of Michigan

COVID-19 deaths are indeed different from other lung failure deaths, according to two recent studies, with 56% of COVID-19 patients dying primarily from the lung damage caused by the virus, compared with 22% of those whose lungs fail due to other causes. But, the researchers conclude, the kind of care needed to help sustain people through the worst cases of all forms of lung failure is highly similar, and just needs to be fine-tuned.

Released: 15-Jan-2021 2:50 PM EST
45% of adults over 65 lack online medical accounts that could help them sign up for COVID-19 vaccinations
Michigan Medicine - University of Michigan

As the vaccination of older adults against COVID-19 begins across the country, new poll data suggests that many of them don’t yet have access to the “patient portal” online systems that could make it much easier for them to schedule a vaccination appointment. In all, 45% of adults aged 65 to 80 had not set up an account with their health provider’s portal system.

Released: 15-Jan-2021 1:30 PM EST
New England Journal of Medicine publishes COVID-19 treatment trial results
University of Texas at San Antonio

A clinical trial involving COVID-19 patients hospitalized at UT Health San Antonio and University Health, among roughly 100 sites globally, found that a combination of the drugs baricitinib and remdesivir reduced time to recovery, according to results published Dec. 11 in the New England Journal of Medicine.

Released: 15-Jan-2021 12:40 PM EST
DNA test can quickly identify pneumonia in patients with severe COVID-19, aiding faster treatment
University of Cambridge

Researchers have developed a DNA test to quickly identify secondary infections in COVID-19 patients, who have double the risk of developing pneumonia while on ventilation than non-COVID-19 patients.

Released: 15-Jan-2021 12:30 PM EST
Fight CRC To Present Research Findings on The Impact of COVID-19 on the Colorectal Cancer Community at 2021 GI ASCO
Fight Colorectal Cancer

Fight Colorectal Cancer presents abstract at Gastrointestinal Cancer Symposium highlighting the need to address the barriers and opportunities for care within the colorectal cancer community during the COVID-19 pandemic

Released: 15-Jan-2021 12:25 PM EST
Technion to Award Honorary Doctorate to Pfizer CEO Dr. Albert Bourla
American Technion Society

Israel's Technion will award an honorary doctorate to Pfizer CEO and Chairman Dr. Albert Bourla, for leading the development of the novel vaccine against SARS-CoV-2, the virus that causes COVID-19. The honorary doctorate will be conferred at the Technion Board of Governors meeting in November 2021.

Released: 15-Jan-2021 11:30 AM EST
UW researchers develop tool to equitably distribute limited vaccines
University of Wisconsin-Madison

Researchers at the University of Wisconsin School of Medicine and Public Health and UW Health have developed a tool that incorporates a person’s age and socioeconomic status to prioritize vaccine distribution among people who otherwise share similar risks due to their jobs.

Showing results

110 of 4573